Repatha®

You are leaving Repatha.eu website and entering another Amgen website

You are now leaving Repatha.eu
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from

Choose a Country ▼

My country is not listed, go to the European website ►

I am not a healthcare professional

HE COUNTS
ON YOU
Because you help to protect him
from another life-changing CV event^1,2

Approved in the EU since 2015³

Repatha^® is a groundbreaking medicine first approved in 2015 for the reduction of LDL-C as an adjunct to statins³ and approved in 2018 for reduction of cardiovascular risk in people with a history of heart attack, stroke or peripheral artery disease.⁴

View the full Repatha^® therapeutic indications

PCSK9 inhibitors endorsed in 2019 ESC/EAS Dyslipidaemia Guidelines⁵

The 2019 update of the ESC/EAS dyslipidaemia guidelines support a “lower is better” approach through more intensive reduction of LDL-C across CV risk categories.⁵
PCSK9 inhibitors like Repatha^® are endorsed as the standard of care with the highest level of recommendation (I A) for very-high-risk secondary prevention patients who have not achieved their LDL-C goals on maximum tolarated statin and ezetimibe therapy.⁵

Discover the 2019 dyslipidaemia guidelines

Repatha^® delivers 25%
CV risk reduction in patients
with a recent MI⁶

Join Amgen and Repatha^®
for sharing practice-changing
science at ESC 2020

With Repatha^®, the majority
of recent MI patients
achieve recommended
LDL-C goals^*6

*In the study, 2690 recent MI patients received Repatha^®, 2254 of whom achieved LDL-C levels <55 mg/dl.
^†25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.

ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EU = European Union; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.

Sabatine MS, et al. Circulation. 2018;138:756-66.
Repatha^® (evolocumab) Summary of Product Characteristics. Last revised: April 2020.
Available at: https://www.ema.europa.eu/en/documents/product-information/repatha-epar-product-information_en.pdf. Accessed: July 2020.
EMA Press release 22/05/2015. Available at: https://www.ema.europa.eu/en/news/first-class-treatment-lower-cholesterol. Accessed: December 2019.
EMA Summary of opinion 22/03/2018.
Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-repatha-ii-17-g_en.pdf. Accessed: July 2020.
Mach F, et al. Eur Heart J. 2020;41(1):111-188.
Gencer B, et al. JAMA Cardiol. 2020; Online first. doi:10.1001/jamacardio.2020.0882.

Terms of Use

HE COUNTS ON YOUBecause you help to protect himfrom another life-changing CV event1,2

Approved in the EU since 20153

PCSK9 inhibitors endorsed in 2019 ESC/EAS Dyslipidaemia Guidelines5

HE COUNTS
ON YOU
Because you help to protect him
from another life-changing CV event^1,2

Approved in the EU since 2015³

PCSK9 inhibitors endorsed in 2019 ESC/EAS Dyslipidaemia Guidelines⁵